MX9800998A - Use of fluconazole for inhibiting the growth of cancers. - Google Patents

Use of fluconazole for inhibiting the growth of cancers.

Info

Publication number
MX9800998A
MX9800998A MX9800998A MX9800998A MX9800998A MX 9800998 A MX9800998 A MX 9800998A MX 9800998 A MX9800998 A MX 9800998A MX 9800998 A MX9800998 A MX 9800998A MX 9800998 A MX9800998 A MX 9800998A
Authority
MX
Mexico
Prior art keywords
cancers
difluorophenyl
triazol
propan
bis
Prior art date
Application number
MX9800998A
Other languages
Spanish (es)
Other versions
MXPA98000998A (en
Inventor
James Berger Camden
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/674,180 external-priority patent/US5908855A/en
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of MXPA98000998A publication Critical patent/MXPA98000998A/en
Publication of MX9800998A publication Critical patent/MX9800998A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A pharmaceutical composition for the treatment of cancers or tumors in mammals is disclosed which comprises 2-(2,4-difluorophenyl)-1,3-bis(1H-1,2,4-triazol-l-yl)propan- 2-ol and its derivatives. A chemotherapeutic agent can be used in conjunction with 2-(2,4-difluorophenyl)-1,3-bis(1H-1,2,4-triazol-l-yl)propan- 2-ol and its derivatives as can potentiators. 2-(2,4-difluorophenyl)-1,3-bis(1H-1,2,4-triazol-l-yl)propan- 2-ol and its derivatives can also be used to treat viral infections, either alone, in conjunction with other anti-viral agents or with a potentiator.
MX9800998A 1995-08-04 1996-07-30 Use of fluconazole for inhibiting the growth of cancers. MX9800998A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US188995P 1995-08-04 1995-08-04
US001889 1995-08-04
US08674180 1996-07-16
US08/674,180 US5908855A (en) 1996-07-16 1996-07-16 Compositions for treating viral infections
PCT/US1996/012474 WO1997005873A2 (en) 1995-08-04 1996-07-30 Use of fluconazole for inhibiting the growth of cancers

Publications (2)

Publication Number Publication Date
MXPA98000998A MXPA98000998A (en) 1998-04-01
MX9800998A true MX9800998A (en) 1998-04-30

Family

ID=26669622

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9800998A MX9800998A (en) 1995-08-04 1996-07-30 Use of fluconazole for inhibiting the growth of cancers.

Country Status (18)

Country Link
EP (1) EP0841921A2 (en)
JP (1) JPH11510187A (en)
KR (1) KR19990036138A (en)
CN (1) CN1195288A (en)
AR (1) AR003175A1 (en)
AU (1) AU711966B2 (en)
BR (1) BR9609966A (en)
CA (1) CA2229024A1 (en)
CZ (1) CZ33798A3 (en)
HU (1) HUP9903420A3 (en)
IL (1) IL123095A0 (en)
MX (1) MX9800998A (en)
NO (1) NO980473L (en)
NZ (2) NZ315184A (en)
PL (1) PL324904A1 (en)
SK (1) SK14198A3 (en)
TR (2) TR199801739T2 (en)
WO (1) WO1997005873A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
FR2742405B1 (en) * 1995-12-13 1998-02-27 Cgea Comp Gen Entre Auto DRIVE UNIT COULD BE COUPLED TO A ROLLING SPEAKER AND RESULTING VEHICLE
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
PE11499A1 (en) * 1997-05-16 1999-03-01 Procter & Gamble TREATMENT OF HIV AND CANCER
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
EP1949911A3 (en) 1998-11-09 2008-08-06 Biogen Idec, Inc. Treatment of chronique lymphocytic leukemia using chimeric anti-CD20 antibody.
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US6407105B1 (en) 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6462062B1 (en) 2000-09-26 2002-10-08 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6608096B1 (en) 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
US7004915B2 (en) * 2001-08-24 2006-02-28 Kci Licensing, Inc. Negative pressure assisted tissue treatment system
EP1895012A1 (en) 2006-08-30 2008-03-05 Universitätsklinikum Freiburg Method for inducing tumor apoptosis by increasing nitric oxide levels
WO2008073961A2 (en) * 2006-12-12 2008-06-19 Emory University Compounds and methods for modulating the silencing of a polynucleotide of interest
WO2019185521A1 (en) * 2018-03-26 2019-10-03 Westfälische Wilhelms-Universität Münster Ergosterol-biosynthesis inhibitor and influenza virus infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0196855A3 (en) * 1985-03-29 1989-04-12 Pfizer Inc. Tioconazole and related compounds for prevention of sexually transmitted diseases and control of herpetic infections
BE1004029A6 (en) * 1990-11-22 1992-09-08 Mol Omer De Pharmaceutical compound and pharmaceutical set for the treatment of cancer
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
US5665751A (en) * 1995-06-07 1997-09-09 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers

Also Published As

Publication number Publication date
NO980473L (en) 1998-04-03
NO980473D0 (en) 1998-02-03
AR003175A1 (en) 1998-07-08
EP0841921A2 (en) 1998-05-20
HUP9903420A3 (en) 2001-12-28
TR199801739T2 (en) 1998-12-21
HUP9903420A2 (en) 2000-03-28
CZ33798A3 (en) 1998-06-17
AU6683396A (en) 1997-03-05
WO1997005873A2 (en) 1997-02-20
JPH11510187A (en) 1999-09-07
PL324904A1 (en) 1998-06-22
WO1997005873A3 (en) 1997-03-27
TR199800270T1 (en) 1998-05-21
KR19990036138A (en) 1999-05-25
IL123095A0 (en) 1998-09-24
NZ315184A (en) 2000-05-26
CN1195288A (en) 1998-10-07
SK14198A3 (en) 1999-03-12
AU711966B2 (en) 1999-10-28
CA2229024A1 (en) 1997-02-20
NZ503921A (en) 2002-03-01
BR9609966A (en) 1999-02-02

Similar Documents

Publication Publication Date Title
MX9800998A (en) Use of fluconazole for inhibiting the growth of cancers.
MX9800945A (en) Use of griseofulvin for inhibiting the growth of cancers.
MX9800944A (en) Use of 1h-1,2,4-triazole derivatives for inhibiting the growth of cancers.
MY116478A (en) Tri-substituted imidazoles having multiple therapeutic properties
BR9604974A (en) Pharmaceutical composition containing benzimidazole to inhibit cancer growth
MX9702382A (en) New pyrimidone derivatives with antifungal activity.
NO174508C (en)
MD1838F2 (en) 5,6-dichlorbenzimidazole derivatives, process for obtaining thereof, pharmaceutical composition and method of treatment or prevention of herpetic viral infections
NZ308391A (en) Use of 1,2,4-triazole derivatives for the manufacture of a medicament for the treatment of cancers
PL322732A1 (en) Pharmaceutic agent containing n-chlorophenyl carbaminates and n-chlorophenyl thiocarbaminates for inhibiting development of viruses and carcinoma
GB2278115B (en) 2-(2-Hydroxyphenyl)-1,3-pyrimidine derivatives and their use as stabilizers for coating compositions
ES8406191A1 (en) Triazole derivative as an antiviral agent
IL104775A (en) Pharmaceutical composition containing triazine derivatives for treating pain or oedema
YU46302A (en) Substituted pyrroles
MX9707808A (en) A pharmaceutical composition containing n-chlorophenylcarbamates and n-chlorophenylthiocarbamates for inhibiting the growth of viruses and cancers.
ES8704464A1 (en) 4(5)-substituted imidazoles.
MX9709712A (en) Use of 1,2,4-triazole derivatives for the manufacture of a medicament for the treatment of cancers.
MY121813A (en) Nucleosides
MX9709530A (en) Use of bis-1,2,4-triazoles for the manufacture of a medicament for the treatment of cancers.
MX9707810A (en) A pharmaceutical composition containing n-phosphonoglycine derivatives for inhibiting the growth of viruses and cancers.
ES8407050A1 (en) Fluoroalkyl indoline derivatives for pharmaceutical use.
MX9707811A (en) A pharmaceutical composition containing n-chlorophenylcarbamates, n-chlorophenylthiocarbamates and n-phosphonoglycine derivatives for inhibiting the growth of cancers and viruses in mammals.
HUP9801596A3 (en) Use of azole compounds for preparing pharmaceutical compositions useful for the treatment of fungal infections, new azole derivatives and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FA Abandonment or withdrawal